New U.S. evidence highlights patterns relevant to harm reduction policy As nicotine pouches (ONPs) continue to expand in the United States, understanding how adult smokers engage with these products is becoming increasingly important for evidence-based regulation. A recent peer-reviewed study using nationally representative data from the Population Assessment of Tobacco and Health (PATH) Study provides…
Across the European Union, tobacco control policy has historically focused on reducing smoking through restrictions, taxation, and public health campaigns. These measures have contributed to steady declines in smoking prevalence over time. However, the pace of change has varied across Member States, and smoking remains a significant public health concern. Within this broader context, Sweden…
Across the European Union, tobacco control policy has long focused on reducing smoking prevalence through a combination of regulatory restrictions, public health campaigns, and excise taxation. These approaches have contributed to meaningful progress over time. However, smoking remains a leading cause of preventable disease, and reducing its impact continues to be a central objective of…
Public health policy often develops through long institutional processes. Regulations are debated, negotiated, and revised through multiple stages of consultation and political review. This is particularly true in the European Union, where legislative frameworks such as the Tobacco Products Directive (TPD) and the Tobacco Excise Directive (TED) shape tobacco and nicotine policy across all Member…
Debates around nicotine policy often focus narrowly on dependence and youth protection. Far less frequently examined, but increasingly discussed in scientific and policy literature, is nicotine’s relationship with cognition and mental health. Emerging research suggests that nicotine may have measurable short-term effects on attention, working memory, and executive function. At the same time, long-standing concerns…
Public debate around tobacco harm reduction (THR) is increasingly shaped not only by science, but by how that science is communicated. As non-combustible nicotine products expand across global markets, the gap between evidence and public understanding has become a central policy challenge. Miscommunication, oversimplification, and emotive framing risk distorting regulatory discussions at precisely the moment…
Debates around tobacco harm reduction are increasingly shaped not only by emerging products and regulatory decisions, but by how science itself is communicated. A recent commentary on misinformation and “clickbait science” in the tobacco harm reduction space highlights a growing concern: that exaggerated claims, selective interpretation of findings, and sensational headlines can distort both public…
Nicotine pouches remain at the centre of the global harm‑reduction conversation — and a major new peer‑reviewed review helps explain why. A new narrative review by Konstantinos Farsalinos in Internal and Emergency Medicine reinforces a clear message: modern, tobacco‑free nicotine pouches sit at the very lowest end of the toxicant‑exposure continuum. Chemical analyses and biomarker…
Recent commentary describing nicotine pouches as “a wolf in sheep’s clothing” reflects legitimate public-health concerns about youth uptake, long-term uncertainty, and nicotine dependence. However, the framing risks obscuring a critical distinction at the heart of modern tobacco control: the difference between absolute risk and relative risk. Nicotine pouches are not risk-free, but the available evidence…
As nicotine pouches continue to attract regulatory attention, discussion has increasingly focused on isolated clinical observations and precautionary warnings, often without sufficient context on real-world use patterns or comparative risk. This imbalance risks obscuring a more important question for public health: how nicotine pouches are actually used, by whom, and how regulation can address legitimate…